Your Health, We Care
With the increase of the global aging population and the improvement of health awareness among menopausal women, the market demand for Fezolinetant continues to grow. According to Evaluate Pharma's prediction, Fezolinetant's sales will reach $1.9 billion by 2028.
Anstelai has applied for patent protection in China for the salt form, solvate form, and crystal form of non zolpidem. The application and protection of these patents undoubtedly provide strong support for the commercialization of non zolpidem tablets.
